Answers are grounded in this paper and cite their sources.
Observational analysis reveals electrostatic interactions enhance DBO inhibitor potency against OXA-48 β-lactamases, suggesting new treatment pathways for resistant strains.
Carbapenemases, β-lactamases hydrolysing carbapenem antibiotics, challenge treatment of multi-drug resistant bacteria. The OXA-48 carbapenemase is widely disseminated in Enterobacterales, necessitating new treatments for producer strains. Diazabicyclooctane (DBO) inhibitors, including avibactam...
No takes yet. Share an insight, caveat, or question.
Hoff et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: